IMMUNETHEP, a company founded in 2013 as a spin-off of the University of Porto, was established in Biocant Park in Cantanhede in 2015. It currently has 11 people on its team and has already developed 3 products (2 vaccines and 1 therapeutic agent – antibodies). It already has 6 international patents granted and 3 others submitted and is focused on developing immunotherapies to prevent and treat infectious diseases, to prevent the spread of what could be the biggest problem on a global scale in terms of public health, AntiMicrobial Resistance (AMR), which is expected to be responsible for more deaths worldwide than cancer.
The company has been developing innovative products, based on its proprietary technology, such as the PNV vaccine, or the UNImAb monoclonal antibodies, which will allow, respectively, to prevent or treat simultaneously and with a single product, infections by 5 multi-resistant bacteria, including the most lethal to humanity. According to a recent WHO report, PNV is the only multi-bacterial vaccine under development in the world.